RU2012125249A - ПРИМЕНЕНИЕ АГОНИСТОВ α2 АДРЕНЕРГИЧЕСКИХ РЕЦЕПТОРОВ ДЛЯ ЛЕЧЕНИЯ ИЛИ ПРЕДОТВРАЩЕНИЯ ПСОРИАЗА - Google Patents
ПРИМЕНЕНИЕ АГОНИСТОВ α2 АДРЕНЕРГИЧЕСКИХ РЕЦЕПТОРОВ ДЛЯ ЛЕЧЕНИЯ ИЛИ ПРЕДОТВРАЩЕНИЯ ПСОРИАЗА Download PDFInfo
- Publication number
- RU2012125249A RU2012125249A RU2012125249/15A RU2012125249A RU2012125249A RU 2012125249 A RU2012125249 A RU 2012125249A RU 2012125249/15 A RU2012125249/15 A RU 2012125249/15A RU 2012125249 A RU2012125249 A RU 2012125249A RU 2012125249 A RU2012125249 A RU 2012125249A
- Authority
- RU
- Russia
- Prior art keywords
- use according
- imidazol
- dihydro
- amine
- drug
- Prior art date
Links
- 201000004681 Psoriasis Diseases 0.000 title claims abstract 7
- 102000030484 alpha-2 Adrenergic Receptor Human genes 0.000 title claims abstract 6
- 108020004101 alpha-2 Adrenergic Receptor Proteins 0.000 title claims abstract 6
- 239000000048 adrenergic agonist Substances 0.000 title claims abstract 3
- 229940126157 adrenergic receptor agonist Drugs 0.000 title claims abstract 3
- 230000002265 prevention Effects 0.000 title claims 2
- 239000003814 drug Substances 0.000 claims abstract 16
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract 14
- 239000001257 hydrogen Substances 0.000 claims abstract 14
- -1 (8-bromo-quinoxalin-6-yl) - (4,5-dihydro-1H-imidazol-2-yl) amine Chemical class 0.000 claims abstract 10
- 125000000217 alkyl group Chemical group 0.000 claims abstract 10
- 150000001875 compounds Chemical class 0.000 claims abstract 10
- 125000003545 alkoxy group Chemical group 0.000 claims abstract 8
- 150000002431 hydrogen Chemical group 0.000 claims abstract 8
- 208000024891 symptom Diseases 0.000 claims abstract 6
- CNIIGCLFLJGOGP-UHFFFAOYSA-N 2-(1-naphthalenylmethyl)-4,5-dihydro-1H-imidazole Chemical compound C=1C=CC2=CC=CC=C2C=1CC1=NCCN1 CNIIGCLFLJGOGP-UHFFFAOYSA-N 0.000 claims abstract 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims abstract 4
- 239000000384 adrenergic alpha-2 receptor agonist Substances 0.000 claims abstract 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract 4
- XYLJNLCSTIOKRM-UHFFFAOYSA-N Alphagan Chemical compound C1=CC2=NC=CN=C2C(Br)=C1NC1=NCCN1 XYLJNLCSTIOKRM-UHFFFAOYSA-N 0.000 claims abstract 3
- 229960003679 brimonidine Drugs 0.000 claims abstract 3
- 239000003937 drug carrier Substances 0.000 claims abstract 2
- 229910052736 halogen Inorganic materials 0.000 claims abstract 2
- 150000002367 halogens Chemical class 0.000 claims abstract 2
- 238000004519 manufacturing process Methods 0.000 claims abstract 2
- UCEAKYGZJUAJRV-UHFFFAOYSA-N n-(4,5-dihydro-1h-imidazol-2-yl)-8-methylquinoxalin-6-amine Chemical compound C=1C2=NC=CN=C2C(C)=CC=1NC1=NCCN1 UCEAKYGZJUAJRV-UHFFFAOYSA-N 0.000 claims abstract 2
- VIOCQZFGYIMNEX-UHFFFAOYSA-N n-(4,5-dihydro-1h-imidazol-2-yl)quinoxalin-5-amine Chemical compound N1CCN=C1NC1=CC=CC2=NC=CN=C12 VIOCQZFGYIMNEX-UHFFFAOYSA-N 0.000 claims abstract 2
- 229960005016 naphazoline Drugs 0.000 claims abstract 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims abstract 2
- 238000011200 topical administration Methods 0.000 claims abstract 2
- 229940079593 drug Drugs 0.000 claims 12
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims 6
- 239000000556 agonist Substances 0.000 claims 3
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 claims 2
- HUCJFAOMUPXHDK-UHFFFAOYSA-N Xylometazoline Chemical compound CC1=CC(C(C)(C)C)=CC(C)=C1CC1=NCCN1 HUCJFAOMUPXHDK-UHFFFAOYSA-N 0.000 claims 2
- 239000006071 cream Substances 0.000 claims 2
- 239000000499 gel Substances 0.000 claims 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 claims 2
- WYWIFABBXFUGLM-UHFFFAOYSA-N oxymetazoline Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C)=C1CC1=NCCN1 WYWIFABBXFUGLM-UHFFFAOYSA-N 0.000 claims 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 claims 1
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 claims 1
- 229930182837 (R)-adrenaline Natural products 0.000 claims 1
- IAOQEOWQCMGOEP-UHFFFAOYSA-N 5-bromo-n-(4,5-dihydro-1h-imidazol-2-yl)-3-methylquinoxalin-6-amine Chemical compound BrC=1C2=NC(C)=CN=C2C=CC=1NC1=NCCN1 IAOQEOWQCMGOEP-UHFFFAOYSA-N 0.000 claims 1
- WJAJPNHVVFWKKL-UHFFFAOYSA-N Methoxamine Chemical compound COC1=CC=C(OC)C(C(O)C(C)N)=C1 WJAJPNHVVFWKKL-UHFFFAOYSA-N 0.000 claims 1
- 239000004909 Moisturizer Substances 0.000 claims 1
- 229920002125 Sokalan® Polymers 0.000 claims 1
- 235000021355 Stearic acid Nutrition 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 239000000443 aerosol Substances 0.000 claims 1
- 229960000541 cetyl alcohol Drugs 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 239000000839 emulsion Substances 0.000 claims 1
- 102000012803 ephrin Human genes 0.000 claims 1
- 108060002566 ephrin Proteins 0.000 claims 1
- 229960005139 epinephrine Drugs 0.000 claims 1
- 239000003349 gelling agent Substances 0.000 claims 1
- 239000003589 local anesthetic agent Substances 0.000 claims 1
- 239000006210 lotion Substances 0.000 claims 1
- 229960005192 methoxamine Drugs 0.000 claims 1
- 230000001333 moisturizer Effects 0.000 claims 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 claims 1
- 229960002748 norepinephrine Drugs 0.000 claims 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 claims 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims 1
- 239000002674 ointment Substances 0.000 claims 1
- 229960001528 oxymetazoline Drugs 0.000 claims 1
- 239000006072 paste Substances 0.000 claims 1
- 229920000058 polyacrylate Polymers 0.000 claims 1
- 239000003755 preservative agent Substances 0.000 claims 1
- 230000002335 preservative effect Effects 0.000 claims 1
- 239000000243 solution Substances 0.000 claims 1
- 239000007921 spray Substances 0.000 claims 1
- 239000008117 stearic acid Substances 0.000 claims 1
- 239000000725 suspension Substances 0.000 claims 1
- 239000004408 titanium dioxide Substances 0.000 claims 1
- 229960000833 xylometazoline Drugs 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 2
- 125000003037 imidazol-2-yl group Chemical group [H]N1C([*])=NC([H])=C1[H] 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/417—Imidazole-alkylamines, e.g. histamine, phentolamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Emergency Medicine (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
1. Применение терапевтически эффективного количества агонистов α2 адренергических рецепторов и фармацевтически приемлемого носителя для получения лекарственного средства для лечения или предотвращения псориаза или симптомов, связанных с ним, у субъекта, где лекарственное средство предназначается для местного введения на участок кожи субъекта, который подвержен воздействию псориаза или симптома, связанного с ним, или склонен к этому.2. Применение по п.1, где агонист α2 адренергических рецепторов выбирается из группы, состоящей из:(1) соединения формулы (I):где каждый из R, Rи Rнезависимо представляет собой водород, галоген, алкил, или алкокси; каждый из Rи Rнезависимо представляет собой водород, алкил или алкокси; и каждый из Rи Rнезависимо представляет собой водород, нитро, алкил или алкокси;(2) соединения формулы (II):где каждый из A, Aи Aнезависимо представляет собой водород или алкил; и Aнезависимо представляет собой водород или гидрокси;(3) соединения формулы (III):где каждый из B, Bи Bнезависимо представляет собой водород, гидрокси или алкокси; и каждый из Bи Bнезависимо представляет собой водород или алкил;(4) соединения формулы (IV):и(5) соединения формулы (V):3. Применение по п.1, где агонист α2 адренергических рецепторов выбирается из группы, состоящей из бримонидина, (8-бром-хиноксалин-6-ил)-(4,5-дигидро-1H-имидазол-2-ил)амина, (8-бром-хиноксалин-5-ил)-(4,5-дигидро-1H-имидазол-2-ил)амина, (5-бром-3-метил-хиноксалин-6-ил)-(4,5-дигидро-1H-имидазол-2-ил)-амина, (5-бром-2-метокси-хиноксалин-6-ил)-(4,5-дигидро-1H-имидазол-2-ил)амина, (4,5-дигидро-1H-имидазол-2-ил)-(8-метил-хиноксалин-6-ил)-амина, (4,5-дигидро-1H-имидазол-2-ил)-хиноксалин-5-ил-амина, нафазолина, тетрагидроза�
Claims (14)
1. Применение терапевтически эффективного количества агонистов α2 адренергических рецепторов и фармацевтически приемлемого носителя для получения лекарственного средства для лечения или предотвращения псориаза или симптомов, связанных с ним, у субъекта, где лекарственное средство предназначается для местного введения на участок кожи субъекта, который подвержен воздействию псориаза или симптома, связанного с ним, или склонен к этому.
2. Применение по п.1, где агонист α2 адренергических рецепторов выбирается из группы, состоящей из:
(1) соединения формулы (I):
где каждый из R1, R2 и R3 независимо представляет собой водород, галоген, алкил, или алкокси; каждый из R4 и R5 независимо представляет собой водород, алкил или алкокси; и каждый из R6 и R7 независимо представляет собой водород, нитро, алкил или алкокси;
(2) соединения формулы (II):
где каждый из A1, A3 и A4 независимо представляет собой водород или алкил; и A2 независимо представляет собой водород или гидрокси;
(3) соединения формулы (III):
где каждый из B1, B2 и B3 независимо представляет собой водород, гидрокси или алкокси; и каждый из B4 и B5 независимо представляет собой водород или алкил;
(4) соединения формулы (IV):
и
(5) соединения формулы (V):
3. Применение по п.1, где агонист α2 адренергических рецепторов выбирается из группы, состоящей из бримонидина, (8-бром-хиноксалин-6-ил)-(4,5-дигидро-1H-имидазол-2-ил)амина, (8-бром-хиноксалин-5-ил)-(4,5-дигидро-1H-имидазол-2-ил)амина, (5-бром-3-метил-хиноксалин-6-ил)-(4,5-дигидро-1H-имидазол-2-ил)-амина, (5-бром-2-метокси-хиноксалин-6-ил)-(4,5-дигидро-1H-имидазол-2-ил)амина, (4,5-дигидро-1H-имидазол-2-ил)-(8-метил-хиноксалин-6-ил)-амина, (4,5-дигидро-1H-имидазол-2-ил)-хиноксалин-5-ил-амина, нафазолина, тетрагидрозалина, оксиметазолина, ксилометазолина, эпинефрина, норэпинефрина, фенилэфрина и метоксамина.
4. Применение по п.3, где агонист α2 адренергических рецепторов представляет собой бримонидин.
5. Применение по п.1, где лекарственное средство содержит 0,01%-5% масс агониста α2 адренергических рецепторов.
6. Применение по п.5, где лекарственное средство содержит 0,05-0,5%, 0,07%-0,7% или 0,1-0,6% масс агониста α2 адренергических рецепторов.
7. Применение по п.5, где лекарственное средство вводится на участок кожи примерно 0,1 г/см2 - примерно 5 г/см2 площади кожи, одно - четыре нанесения в день.
8. Применение по п.1, где субъекту дополнительно вводится, по меньшей мере, еще одно дополнительное лечение и лекарственное средство против псориаза или симптомов, связанных с ним.
9. Применение по п.1, где лекарственное средство дополнительно содержит диоксид титана.
10. Применение по п.1, где лекарственное средство находится в форме, выбранной из группы, состоящей из спреев, мистов, аэрозолей, растворов, лосьонов, гелей, кремов, притираний, паст, мазей, эмульсий и суспензий.
11. Применение по п.1, где лекарственное средство представляет собой водный гель, содержащий воду, и гелеобразующее для воды количество фармацевтически приемлемого гелеобразующего агента, выбранного из группы, состоящей из карбомеров, глицеринполиакрилата и их смесей, и лекарственное средство имеет физиологически приемлемый pH.
12. Применение по п.1, где лекарственное средство является, по меньшей мере, одним из крема и притирания, каждый из них содержит агент, выбранный из группы, состоящей из стеариновой кислоты, стеарилового спирта, цетилового спирта, глицерина, воды и их смесей, и лекарственное средство имеет физиологически приемлемый pH.
13. Применение по п.1, где лекарственное средство дополнительно содержит, по меньшей мере, один дополнительный фармацевтически активный ингредиент для лечения или предотвращения псориаза или симптомов, связанных с ним.
14. Применение по п.1, где лекарственное средство дополнительно содержит консервант, местный анестетик и увлажнитель кожи.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12/621,942 | 2009-11-19 | ||
| US12/621,942 US8394800B2 (en) | 2009-11-19 | 2009-11-19 | Method for treating psoriasis |
| PCT/US2010/057184 WO2011075267A1 (en) | 2009-11-19 | 2010-11-18 | Use of alpha 2 adrenergic receptor agonists for treating or preventing psoriasis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2012125249A true RU2012125249A (ru) | 2013-12-27 |
| RU2538729C2 RU2538729C2 (ru) | 2015-01-10 |
Family
ID=43729952
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2012125249/15A RU2538729C2 (ru) | 2009-11-19 | 2010-11-18 | Применение агонистов альфа 2 адренергических рецепторов для лечения или предотвращения псориаза |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US8394800B2 (ru) |
| EP (1) | EP2501373B1 (ru) |
| JP (1) | JP5680660B2 (ru) |
| KR (2) | KR20130106439A (ru) |
| CN (1) | CN102844025B (ru) |
| AU (1) | AU2010332233C1 (ru) |
| BR (1) | BR112012012131A2 (ru) |
| CA (1) | CA2781112C (ru) |
| ES (1) | ES2532527T3 (ru) |
| MX (1) | MX2012005790A (ru) |
| NZ (1) | NZ600333A (ru) |
| RU (1) | RU2538729C2 (ru) |
| WO (1) | WO2011075267A1 (ru) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8410102B2 (en) * | 2003-05-27 | 2013-04-02 | Galderma Laboratories Inc. | Methods and compositions for treating or preventing erythema |
| US7439241B2 (en) * | 2003-05-27 | 2008-10-21 | Galderma Laboratories, Inc. | Compounds, formulations, and methods for treating or preventing rosacea |
| US8394800B2 (en) | 2009-11-19 | 2013-03-12 | Galderma Laboratories, L.P. | Method for treating psoriasis |
| JP5747391B2 (ja) | 2010-03-26 | 2015-07-15 | ガルデルマ・リサーチ・アンド・デヴェロップメント | 紅斑の安全かつ有効な治療のための改善された方法および組成物 |
| WO2011117378A2 (en) | 2010-03-26 | 2011-09-29 | Galderma Research & Development | Improved methods and compositions for safe and effective treatment of telangiectasia |
| US8492422B2 (en) * | 2010-09-16 | 2013-07-23 | Allergan, Inc. | Ester pro-drugs of [3-(1-(1H-imidazol-4-yl)ethyl)-2-methylphenyl] methanol for treating skin diseases and conditions |
| US20120076738A1 (en) * | 2010-09-28 | 2012-03-29 | Michael Graeber | Combination treatment for dermatological conditions |
| NO2444068T3 (ru) | 2010-10-21 | 2014-12-20 | ||
| US8053427B1 (en) * | 2010-10-21 | 2011-11-08 | Galderma R&D SNC | Brimonidine gel composition |
| FR2977493B1 (fr) * | 2011-07-05 | 2014-02-14 | Galderma Res & Dev | Nouvelle composition anesthesique stable pour la reduction des reactions cutanees |
| WO2013016072A1 (en) * | 2011-07-22 | 2013-01-31 | Allergan, Inc. | Pharmaceutical compositions comprising 4-bromo-n-(imidazolidin-2-ylidene)-1h-benzimidazol-5-amine for treating skin diseases |
| UA109359C2 (xx) | 2011-11-10 | 2015-08-10 | Лікування захворювань і станів шкіри 7-(1h-імідазол-4-ілметил)-5,6,7,8-тетрагідрохіноліном | |
| US9283217B2 (en) | 2011-11-10 | 2016-03-15 | Allergan, Inc. | Pharmaceutical compositions comprising 7-(1 H-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions |
| US9861645B2 (en) | 2012-12-28 | 2018-01-09 | Rak Holdings Llc | Anti-itch scalp treatment compositions and combinations |
| US20140350106A1 (en) * | 2013-05-22 | 2014-11-27 | Professional Compounding Centers Of America | Urea Silicone Gel for Scars and Hydration Treatment and Method of Using Same |
| KR20160037791A (ko) * | 2014-09-29 | 2016-04-06 | (주)네오팜 | 건성 치료용 산성 외용제 조성물 |
| AU2020264808B2 (en) * | 2019-05-01 | 2025-01-02 | Clexio Biosciences Ltd. | Methods of treating pruritus |
| US20220211672A1 (en) * | 2019-05-01 | 2022-07-07 | Clexio Biosciences Ltd. | Methods of treating pruritus |
Family Cites Families (80)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3278447A (en) | 1963-12-02 | 1966-10-11 | Cloro Bac Products Inc | Process for stabilizing chlorine dioxide solution |
| US3560501A (en) | 1966-09-15 | 1971-02-02 | Ciba Geigy Corp | Process for making dihydroquinazolines |
| US3723432A (en) | 1968-11-12 | 1973-03-27 | Sandoz Ag | 1-substituted-4-aryl-2(1h)-quinazolinones and their preparation |
| US3594380A (en) | 1969-02-18 | 1971-07-20 | American Home Prod | Isoquinolin-1(2h)-ones |
| BE766039A (fr) | 1971-04-21 | 1971-09-16 | Labofina Sa | Nouveaux polymeres contenant des unites de pyrazole et procede de preparation de ces polymeres. |
| US3740442A (en) | 1972-01-14 | 1973-06-19 | Sandoz Ag | 2-isopropylaminobenzophenones in treating inflammation |
| BE795970A (fr) | 1972-02-29 | 1973-08-27 | Pfizer | Nouveaux derives de quinoleine, quinoxaline et quinazoline er composition pharmaceutiques les contenant |
| US4029792A (en) | 1972-02-29 | 1977-06-14 | Pfizer Inc. | (2-Imidazolin-2-ylamino) substituted -quinoxalines and -quinazolines as antihypertensive agents |
| US4164570A (en) | 1973-09-24 | 1979-08-14 | David Clough | Stabilized aqueous catecholamine solutions |
| US4201211A (en) | 1977-07-12 | 1980-05-06 | Alza Corporation | Therapeutic system for administering clonidine transdermally |
| US4285967A (en) | 1978-06-30 | 1981-08-25 | Estee Lauder Inc. | Cosmetic preparation for reducing redness of blemishes |
| US4256763A (en) | 1978-09-19 | 1981-03-17 | Mchugh John E | Treatment of herpes simplex infections and acne |
| US5166331A (en) | 1983-10-10 | 1992-11-24 | Fidia, S.P.A. | Hyaluronics acid fractions, methods for the preparation thereof, and pharmaceutical compositions containing same |
| CA2003198C (en) | 1988-11-29 | 1995-03-21 | Anthony J. Dziabo, Jr. | Aqueous ophthalmic solutions and method for preserving same |
| FR2648709A1 (fr) | 1989-06-23 | 1990-12-28 | Boehringer Ingelheim France | Nouvelle utilisation de derives de 1-phenyl-2-aminoethanol en tant que moyens cicatrisants |
| US5112822A (en) | 1989-10-12 | 1992-05-12 | Allergan, Inc. | (2-imidazolin-2-ylamino) quinoxaline derivatives and methods for using same |
| US5204347A (en) | 1989-10-12 | 1993-04-20 | Allergan, Inc. | Methods for using (2-imidazolin-2-ylamino) tetrahydroquinoxalines |
| US5198442A (en) | 1989-10-12 | 1993-03-30 | Allergan, Inc. | (2-imidazolin-2-ylamino) quinoxaline derivatives and methods for using same |
| US5077292A (en) | 1989-10-12 | 1991-12-31 | Allergan, Inc. | (2-imidazolin-2-ylamino) tetrahydroquinoxalines and methods for using same |
| US5326763A (en) | 1989-10-12 | 1994-07-05 | Allergan, Inc. | Methods for using (2-imidazolin-2-ylamino) quinoxaline derivatives |
| US5021416A (en) | 1989-10-31 | 1991-06-04 | Allergan, Inc. | Method for using (2-imidazolin-2-ylamino) quinoxalines to reduce or maintain intraocular pressure |
| US5237072A (en) | 1990-02-06 | 1993-08-17 | Allergan, Inc. | Method for producing amino-2-imidazoline derivatives |
| US5130441A (en) | 1990-02-06 | 1992-07-14 | Allergan, Inc. | Method for producing amino-2-imidazoline derivatives |
| US5721237A (en) | 1991-05-10 | 1998-02-24 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties |
| US5736165A (en) | 1993-05-25 | 1998-04-07 | Allergan | In-the-eye use of chlorine dioxide-containing compositions |
| JP3683908B2 (ja) | 1993-10-13 | 2005-08-17 | アラーガン、インコーポレイテッド | （２−イミダゾリン−２−イルアミノ）キノキサリン誘導体の使用方法 |
| US6323204B1 (en) | 1993-10-13 | 2001-11-27 | Allergan | Methods for using (2-imidazolin-2-ylamino) quinoxaline derivatives |
| US6117871A (en) | 1993-12-17 | 2000-09-12 | The Procter & Gamble Company | 6-(2-imidazolinylamino)quinoxaline compounds useful as alpha-2 adrenoceptor agonists |
| WO1996013267A2 (en) | 1994-10-27 | 1996-05-09 | Allergan | Combinations of prostaglandins and brimonidine or derivatives thereof for the treatment of glaucoma |
| US5688808A (en) | 1994-12-22 | 1997-11-18 | Ligand Pharmaceuticals Incorporated | Steroid receptor modulator compounds and methods |
| WO1996025163A1 (en) | 1995-02-14 | 1996-08-22 | Board Of Supervisors Or Louisiana State Universityof Agricultural And Mechanical College Through Itsmedical Center | Treatment of herpes simplex viruses |
| US6194415B1 (en) | 1995-06-28 | 2001-02-27 | Allergan Sales, Inc. | Method of using (2-imidazolin-2-ylamino) quinoxoalines in treating neural injury |
| US5720962A (en) | 1995-10-04 | 1998-02-24 | Au Pharmaceuticals, Inc. | Analgesic lotion for hemorrhoids and method of making such lotion |
| US6441047B2 (en) | 1995-11-17 | 2002-08-27 | Alcon Manufacturing Ltd.. | Combination therapy for treating glaucoma |
| US5753637A (en) | 1996-10-09 | 1998-05-19 | Ideal Ideas, Inc. | Method of treating acne conditions |
| US5916574A (en) | 1996-10-09 | 1999-06-29 | Ideal Ideas, Inc. | Method of treating natural poison skin conditions |
| EP0969790A2 (de) | 1997-02-21 | 2000-01-12 | Beiersdorf Aktiengesellschaft | Zubereitungen für die behandlung von rosacea |
| US6159944A (en) | 1998-02-27 | 2000-12-12 | Synchroneuron, Llc | Method for treating painful conditions of the anal region and compositions therefor |
| ES2220257T1 (es) | 1998-03-11 | 2004-12-16 | Kabushiki Kaisha Soken | Agentes normalizadores para la piel. |
| US6432934B1 (en) | 1998-08-06 | 2002-08-13 | Advanced Vision Research | Methods and compositions for topical treatment of eye surface inflammation and related dry eye disease |
| US20030087962A1 (en) | 1998-10-20 | 2003-05-08 | Omeros Corporation | Arthroscopic irrigation solution and method for peripheral vasoconstriction and inhibition of pain and inflammation |
| US20020197300A1 (en) | 1999-02-22 | 2002-12-26 | Schultz Clyde L. | Drug delivery system for anti-glaucomatous medication |
| AU5331200A (en) | 1999-06-11 | 2001-01-02 | Ohio State University Research Foundation, The | Methods and compositions for treating raynaud's phenomenon and scleroderma |
| US6147102A (en) | 1999-10-26 | 2000-11-14 | Curatek Pharmaceuticals Holding, Inc. | Clonidine preparations |
| US20030077301A1 (en) | 1999-12-16 | 2003-04-24 | Maibach Howard I. | Topical pharmaceutical composition for the treatment of inflammatory dermatoses |
| US6294553B1 (en) | 2000-02-15 | 2001-09-25 | Allergan Sales, Inc. | Method for treating ocular pain |
| US6284765B1 (en) | 2000-04-27 | 2001-09-04 | The University Of North Texas Health Science Center At Fort Worth | (+) naloxone and epinephrine combination therapy |
| US6444681B1 (en) | 2000-06-09 | 2002-09-03 | The Ohio State University Research Foundation | Methods and compositions for treating Raynaud's Phenomenon and scleroderma |
| US6468989B1 (en) | 2000-07-13 | 2002-10-22 | Dow Pharmaceutical Sciences | Gel compositions containing metronidazole |
| US6387383B1 (en) | 2000-08-03 | 2002-05-14 | Dow Pharmaceutical Sciences | Topical low-viscosity gel composition |
| US7211267B2 (en) | 2001-04-05 | 2007-05-01 | Collagenex Pharmaceuticals, Inc. | Methods of treating acne |
| US20020198209A1 (en) | 2001-05-03 | 2002-12-26 | Allergan Sales Inc. | Compositions having enhanced pharmacokinetic characteristics |
| AU2002256471B2 (en) | 2001-05-03 | 2007-05-24 | Allergan, Inc. | Compositions having enhanced pharmacokinetic characteristics |
| US6680062B2 (en) | 2001-10-05 | 2004-01-20 | Color Access, Inc. | Anti-irritating rosacea treatment |
| US7345065B2 (en) | 2002-05-21 | 2008-03-18 | Allergan, Inc. | Methods and compositions for alleviating pain |
| US20040266776A1 (en) | 2003-06-25 | 2004-12-30 | Gil Daniel W. | Methods of preventing and reducing the severity of stress-associated conditions |
| US20040092482A1 (en) | 2002-11-07 | 2004-05-13 | Gupta Shyam K. | Hydroxy acids based delivery systems for skin resurfacing and anti-aging compositions |
| US20040156873A1 (en) | 2003-02-10 | 2004-08-12 | Gupta Shyam K. | Topically Bioavailable Acne and Rosacea Treatment Compositions |
| US20040220259A1 (en) | 2003-04-04 | 2004-11-04 | Yu Ruey J. | Topical treatment of dermatological disorders associated with reactive or dilated blood vessels |
| EP1622554A4 (en) | 2003-05-15 | 2008-01-02 | Bioform Medical Inc | COMPOSITIONS CONTAINING A COMBINATION OF A PHARMACEUTICAL AGENT OR A COSMETIC AGENT AND AN OXY-GROUP-WEARING AROMATIC ALDEHYDE |
| US7439241B2 (en) | 2003-05-27 | 2008-10-21 | Galderma Laboratories, Inc. | Compounds, formulations, and methods for treating or preventing rosacea |
| US7141597B2 (en) * | 2003-09-12 | 2006-11-28 | Allergan, Inc. | Nonsedating α-2 agonists |
| US20050059664A1 (en) * | 2003-09-12 | 2005-03-17 | Allergan, Inc. | Novel methods for identifying improved, non-sedating alpha-2 agonists |
| US20050020600A1 (en) | 2003-07-23 | 2005-01-27 | Scherer Warren J. | Methods of treating cutaneous flushing using selective alpha-2-adrenergic receptor agonists |
| US20050059744A1 (en) | 2003-09-12 | 2005-03-17 | Allergan, Inc. | Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions |
| JP5165242B2 (ja) | 2003-09-12 | 2013-03-21 | アラーガン、インコーポレイテッド | 疼痛およびα２アドレナリン受容体が関与する他の状態の処置のための方法および組成物 |
| US7285544B2 (en) * | 2003-11-18 | 2007-10-23 | Bernstein Eric F | Use of nitroxides in treating skin disease |
| US7239705B2 (en) | 2003-12-10 | 2007-07-03 | Motorola Inc. | Apparatus and method for broadcast services transmission and reception |
| EP1706148A2 (en) * | 2004-01-14 | 2006-10-04 | Gilead Sciences, Inc. | Lipid-based dispersions useful for drug delivery |
| US7812049B2 (en) | 2004-01-22 | 2010-10-12 | Vicept Therapeutics, Inc. | Method and therapeutic/cosmetic topical compositions for the treatment of rosacea and skin erythema using α1-adrenoceptor agonists |
| CN104490884A (zh) * | 2004-05-25 | 2015-04-08 | 桑斯罗萨医药发展公司 | 治疗或预防炎症性皮肤疾病的化合物、制剂及方法 |
| CA2593537A1 (en) * | 2005-01-12 | 2006-07-20 | S.U.L.V.E. Ltd. | Methods and pharmaceutical compositions useful for treating psoriasis |
| US20070082070A1 (en) | 2005-10-11 | 2007-04-12 | Stookey Evangeline L | Treating skin disorders |
| JP2009528382A (ja) * | 2006-03-01 | 2009-08-06 | トリストラータ・インコーポレイテッド | タール応答性皮膚疾患の局所治療のための組成物及び方法 |
| US20090061020A1 (en) * | 2007-08-31 | 2009-03-05 | Theobald Klaus P | Brimonidine Compositions for Treating Erythema |
| JP2011512345A (ja) * | 2008-02-15 | 2011-04-21 | ボーン・セラピューティクス | 骨関節疾患の治療及び／または予防において使用する医薬組成物 |
| EP2090307A1 (en) | 2008-02-15 | 2009-08-19 | Bone Therapeutics | Pharmaceutical composition for the treatment or prevention of osteoarticular diseases |
| CN101951903A (zh) * | 2008-02-15 | 2011-01-19 | 骨治疗公司 | 用于治疗或预防骨关节疾病的药物组合物 |
| US8394800B2 (en) | 2009-11-19 | 2013-03-12 | Galderma Laboratories, L.P. | Method for treating psoriasis |
| US8053427B1 (en) | 2010-10-21 | 2011-11-08 | Galderma R&D SNC | Brimonidine gel composition |
-
2009
- 2009-11-19 US US12/621,942 patent/US8394800B2/en not_active Expired - Fee Related
-
2010
- 2010-11-18 JP JP2012540047A patent/JP5680660B2/ja not_active Expired - Fee Related
- 2010-11-18 KR KR1020137021672A patent/KR20130106439A/ko not_active Withdrawn
- 2010-11-18 CA CA2781112A patent/CA2781112C/en not_active Expired - Fee Related
- 2010-11-18 MX MX2012005790A patent/MX2012005790A/es active IP Right Grant
- 2010-11-18 AU AU2010332233A patent/AU2010332233C1/en not_active Ceased
- 2010-11-18 NZ NZ600333A patent/NZ600333A/en not_active IP Right Cessation
- 2010-11-18 CN CN201080051989.9A patent/CN102844025B/zh not_active Expired - Fee Related
- 2010-11-18 KR KR1020127015875A patent/KR101374907B1/ko not_active Expired - Fee Related
- 2010-11-18 BR BR112012012131A patent/BR112012012131A2/pt not_active IP Right Cessation
- 2010-11-18 EP EP10779906.6A patent/EP2501373B1/en not_active Not-in-force
- 2010-11-18 ES ES10779906.6T patent/ES2532527T3/es active Active
- 2010-11-18 WO PCT/US2010/057184 patent/WO2011075267A1/en not_active Ceased
- 2010-11-18 RU RU2012125249/15A patent/RU2538729C2/ru not_active IP Right Cessation
-
2013
- 2013-03-05 US US13/785,802 patent/US9072739B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| KR20120129878A (ko) | 2012-11-28 |
| US8394800B2 (en) | 2013-03-12 |
| EP2501373B1 (en) | 2015-02-25 |
| MX2012005790A (es) | 2012-09-28 |
| HK1175698A1 (en) | 2013-07-12 |
| EP2501373A1 (en) | 2012-09-26 |
| JP2013511534A (ja) | 2013-04-04 |
| US20110118267A1 (en) | 2011-05-19 |
| KR101374907B1 (ko) | 2014-03-14 |
| ES2532527T3 (es) | 2015-03-27 |
| KR20130106439A (ko) | 2013-09-27 |
| JP5680660B2 (ja) | 2015-03-04 |
| CA2781112A1 (en) | 2011-06-23 |
| BR112012012131A2 (pt) | 2019-09-24 |
| RU2538729C2 (ru) | 2015-01-10 |
| WO2011075267A1 (en) | 2011-06-23 |
| NZ600333A (en) | 2014-05-30 |
| AU2010332233A1 (en) | 2012-06-14 |
| AU2010332233C1 (en) | 2013-12-19 |
| US9072739B2 (en) | 2015-07-07 |
| CN102844025B (zh) | 2014-11-19 |
| CN102844025A (zh) | 2012-12-26 |
| US20130184283A1 (en) | 2013-07-18 |
| CA2781112C (en) | 2015-01-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2012125249A (ru) | ПРИМЕНЕНИЕ АГОНИСТОВ α2 АДРЕНЕРГИЧЕСКИХ РЕЦЕПТОРОВ ДЛЯ ЛЕЧЕНИЯ ИЛИ ПРЕДОТВРАЩЕНИЯ ПСОРИАЗА | |
| EP1631293B1 (en) | Compounds, formulations, and methods for treating or preventing rosacea | |
| AU2010313643B2 (en) | Methods of treating or preventing acute erythema | |
| US8440688B2 (en) | Compounds, formulations and methods for reducing skin wrinkles, creasing and sagging | |
| AU2005247467B2 (en) | Compounds, formulations, and methods for treating or preventing inflammatory skin disorders | |
| JP2008500356A5 (ru) | ||
| RU2012124904A (ru) | КОМБИНАЦИЯ АГОНИСТА α2-АДРЕНЕРГИЧЕСКИХ РЕЦЕПТОРОВ И НЕСТЕРОИДНОГО ПРОТИВОВОСПАЛИТЕЛЬНОГО СРЕДСТВА ДЛЯ ЛЕЧЕНИЯ ИЛИ ПРОФИЛАКТИКИ ВОСПАЛИТЕЛЬНОГО ПОРАЖЕНИЯ КОЖИ | |
| US20200390762A1 (en) | Method of treating hand-foot syndrome and symptoms associated therewith | |
| HK1084591B (en) | Compounds, formulations, and methods for treating or preventing rosacea | |
| HK1174537A (en) | Compounds, formulations, and methods for treating or preventing inflammatory skin disorders |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20171119 |